Publications by authors named "P Omede"
Article Synopsis
- Researchers studied 1,729 patients with coronary artery aneurysms (CAAs) to understand their clinical characteristics and predict outcomes, using data from an international registry across 9 countries.
- The majority of patients were male (78.6%) averaging 66 years old, with significant cardiovascular issues such as coronary artery disease (85.8%) and a median of 1 aneurysm per patient, primarily affecting the left anterior descending artery.
- During a median follow-up of about 45 months, 21.9% of patients died, and 37.1% experienced major adverse cardiovascular events; factors like age, diabetes, and kidney disease were linked to worse outcomes.
Article Synopsis
- The study evaluates the performance of ultrathin drug-eluting stents (DES) versus thin-strut DES and drug-eluting balloons (DEB) in treating in-stent restenosis (ISR) in patients.
- Results show that ultrathin DES significantly lowers the risk of adverse events, including cardiac death and need for revascularization, when compared to both thin-strut DES and DEBs after three years of follow-up.
- Additionally, in patients with diffuse ISR, ultrathin DES outperformed thin-strut DES in reducing risks of target lesion revascularization (TLR) and target vessel revascularization (TVR).
Stratifying prognosis following coronary bifurcation percutaneous coronary intervention (PCI) is an unmet clinical need that may be fulfilled through the adoption of machine learning (ML) algorithms to refine outcome predictions. We sought to develop an ML-based risk stratification model built on clinical, anatomical, and procedural features to predict all-cause mortality following contemporary bifurcation PCI. Multiple ML models to predict all-cause mortality were tested on a cohort of 2393 patients (training, n = 1795; internal validation, n = 598) undergoing bifurcation PCI with contemporary stents from the real-world RAIN registry.
View Article and Find Full Text PDFIntroduction: For acute coronary syndrome (ACS) patients treated with percutaneous coronary intervention (PCI), the choice of the duration and kind of dual antiplatelet therapy (DAPT) offering the most accurate balance between ischemic and bleeding risk remains unknown.
Evidence Acquisition: A network meta-analysis was performed including all Randomized Controlled Trials (RCTs) comparing different DAPT regimens and duration in ACS patients undergoing PCI. Trial-defined MACE and major bleedings were the primary endpoints.